A common STEP in the synaptic pathology of diverse neuropsychiatric disorders

Yale Journal of Biology and Medicine

Volumn 85, Issue 4, 2012, Pages 481-490

  Johnson, Micah A ^a,b   Lombroso, Paul J ^a,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Fragile X syndrome; Neuropsychiatric disorders; NMDAR trafficking; Schizophrenia; STEP; Synaptic plasticity; Translational neuroscience

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID RECEPTOR; AMYLOID PRECURSOR PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROTEIN KINASE FYN; PROTEIN TYROSINE PHOSPHATASE; STRIATAL ENRICHED PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; DISEASE ACTIVITY; FRAGILE X SYNDROME; HUMAN; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MENTAL DISEASE; MOLECULAR MODEL; MOLECULAR PATHOLOGY; NERVE CELL PLASTICITY; NEUROPATHOLOGY; NONHUMAN; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYNAPTIC INHIBITION;

ALZHEIMER DISEASE; ANIMALS; FRAGILE X SYNDROME; HUMANS; RECEPTORS, NEUROTRANSMITTER; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYNAPSES;

EID: 84871541961     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Huttenlocher PR. Dendritic and synaptic pathology in mental retardation. Pediatr Neurol. 1991;7(2):79-85.
2. Blanpied TA, Ehlers MD. Microanatomy of dendritic spines: emerging principles of synaptic pathology in psychiatric and neurological disease. Biol Psychiatry. 2004;55(12):1121-7.
3. Fiala JC, Spacek J, Harris KM. Dendritic spine pathology: cause or consequence of neurological disorders? Brain Res Brain Res Rev. 2002;39(1):29-54.
4. Oever MCVD, Spijker S, Smit AB. The Synaptic Plasticity of Drug Addiction. In: Kreutz MR, Sala C, editors. Synaptic Plasticity. Vienna: Springer Vienna; 2012. p. 469-91.
5. Garner CC, Wetmore DZ. Synaptic pathology of Down syndrome. Adv Exp Med Biol. 2012;970:451-68.
6. Lombroso PJ, Murdoch G, Lerner M. Molecular characterization of a protein-tyrosinephosphatase enriched in striatum. Proc Natl Acad Sci USA. 1991;88(16):7242-6.
7. Lombroso PJ, Naegele JR, Sharma E, Lerner M. A protein tyrosine phosphatase expressed within dopaminoceptive neurons of the basal ganglia and related structures. J Neurosci. 1993;13(7):3064-74.
8. Bult A, Zhao F, Dirkx R Jr., Sharma E, Lukacsi E, Solimena M, et al. STEP 61: A member of a family of brain-enriched PTPs is localized to the endoplasmic reticulum. J Neurosci. 1996;16(24):7821-31.
9. Oyama T, Goto S, Nishi T, Sato K, Yamada K, Yoshikawa M, et al. Immunocytochemical localization of the striatal enriched protein tyrosine phosphatase in the rat striatum. Neuroscience 1995;69(3):869-80.
10. Goebel-Goody SM, Davies KD, Alvestad Linger RM, Freund RK, Browning MD. Phospho-regulation of synaptic and extrasynaptic N-methyl-d-aspartate receptors in adult hippocampal slices. Neuroscience. 2009;158(4):1446-59.
11. Boulanger LM, Wahle P, During MJ. Cellular and molecular characterization of a brain-enriched protein tyrosine phosphatase. J Neurosci. 1995;15(2):1532-44.
12. Lorber B, Berry M, Hendriks W, den Hertog J, Pulido R, Logan A. Stimulated regeneration of the crushed adult rat optic nerve correlates with attenuated expression of the protein tyrosine phosphatases RPTPalpha, STEP, and LAR. Mol Cell Neurosci. 2004;27(4):404-16.
13. Paul S, Snyder GL, Yokakura H, Picciotto MR, Nairn AC, Lombroso PJ. The Dopamine/D1 receptor mediates the phosphorylation and inactivation of the protein tyrosine phosphatase STEP via a PKA-dependent pathway. J Neurosci. 2000;20(15):5630-8.
14. Paul S, Nairn AC, Wang P, Lombroso PJ. NMDA-mediated activation of the tyrosine phosphatase STEP regulates the duration of ERK signaling. Nat Neurosci. 2003;6(1):34-42.
15. Xu J, Kurup P, Zhang Y, Goebel-Goody SM, Wu PH, Hawasli AH, et al. Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP. J Neurosci. 2009;29(29):9330-43.
16. Deb I, Poddar R, Paul S. Oxidative stress-induced oligomerization inhibits the activity of the non-receptor tyrosine phosphatase STEP61. J Neurochem. 2011;116(6):1097-111.
17. Kurup P, Zhang Y, Xu J, Venkitaramani DV, Haroutunian V, Greengard P, et al. Abetamediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61. J Neurosci. 2010;30(17):5948-57.
18. Zhang Y, Venkitaramani DV, Gladding CM, Zhang Y, Kurup P, Molnar E, et al. The tyro-sine phosphatase STEP mediates AMPA receptor endocytosis after metabotropic glutamate receptor stimulation. J Neurosci. 2008;28(42):10561-6.
19. Valjent E, Pascoli V, Svenningsson P, Paul S, Enslen H, Corvol J-C, et al. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc Natl Acad Sci USA. 2005;102(2):491-6.
20. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005;8(8):1051-8.
21. Nguyen T-H, Liu J, Lombroso PJ. Striatal enriched phosphatase 61 dephosphorylates Fyn at phosphotyrosine 420. J Biol Chem. 2002;277(27):24274-9.
22. Zhang Y, Kurup P, Xu J, Anderson GM, Greengard P, Nairn AC, et al. Reduced levels of the tyrosine phosphatase STEP block β amyloid-mediated GluA1/GluA2 receptor internalization. J Neurochem. 2011;119(3):664-72.
23. Xu J, Kurup P, Bartos JA, Patriarchi T, Hell JW, Lombroso PJ. Striatal-enriched Protein-tyrosine Phosphatase (STEP) Regulates Pyk2 Kinase Activity. J Biol Chem. 2012;287(25):20942-56.
24. Munoz JJ, Tarrega C, Blanco-Aparicio C, Pulido R. Differential interaction of the tyrosine phosphatases PTP-SL, STEP and HePTP with the mitogen-activated protein kinases ERK1/2 and p38alpha is determined by a kinase specificity sequence and influenced by reducing agents. Biochem J. 2003;372(Pt 1):193-201.
25. Poddar R, Deb I, Mukherjee S, Paul S. NR2B-NMDA receptor mediated modulation of the tyrosine phosphatase STEP regulates glutamate induced neuronal cell death. J Neurochem. 2010;115(6):1350-62.
26. Perez-Otano I, Ehlers MD. Homeostatic plasticity and NMDA receptor trafficking. Trends Neurosci. 2005;28(5):229-38.
27. Kerchner G, Nicoll RA. Silent synapses and the emergence of a postsynaptic mechanism for LTP. Nat Rev Neurosci. 2008;9(11):813-25.
28. Pelkey KA, Askalan R, Paul S, Kalia LV, Nguyen TH, Pitcher GM, et al. Tyrosine phosphatase STEP is a tonic brake on induction of long-term potentiation. Neuron. 2002;34(1):127-38.
29. Zhang Y, Kurup P, Xu J, Carty N, Fernandez SM, Nygaard HB, et al. Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model. Proc Natl Acad Sci USA. 2010;107(44):19014-9.
30. Schafe GE, Atkins CM, Swank MW, Bauer EP, Sweatt JD, LeDoux JE. Activation of ERK/MAP kinase in the amygdala is required for memory consolidation of pavlovian fear conditioning. J Neurosci. 2000;20(21):8177-87.
31. Sweatt JD. Mitogen-activated protein kinases in synaptic plasticity and memory. Curr Opin Neurobiol. 2004;14(3):311-7.
32. Wiegert JS, Bading H. Activity-dependent calcium signaling and ERK-MAP kinases in neurons: a link to structural plasticity of the nucleus and gene transcription regulation. Cell Calcium. 2011;49(5):296-305.
33. Paul S, Connor J. NR2B-NMDA receptormediated increases in intracellular Ca2+ concentration regulate the tyrosine phosphatase, STEP, and ERK MAP kinase signaling. J Neurochem. 2010;114(4):1107-18.
34. Paul S, Olausson P, Venkitaramani DV, Ruchkina I, Timothy D, Tronson N, et al. The protein tyrosine phosphatase STEP gates long-term potentiation and fear memory in the lateral amygdala. Biol Psychiatry. 2007;61(9):1049-61.
35. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007;3(3):186-91.
36. Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148(6):1204-22.
37. Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Elsevier Ltd; 2012.
38. Alzheimer's Disease International. World Alzheimer Report: The Global Economic Impact of Dementia; 2010.
39. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572-80.
40. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298(5594):789-91.
41. Goate A, Hardy J. Twenty years of Alzheimer's disease-causing mutations. J Neurochem. 2012;120(Suppl 1):3-8.
42. Yi JJ, Ehlers MD. Emerging roles for ubiquitin and protein degradation in neuronal function. Pharmacol Rev. 2007;59(1):14-39.
43. Chin J, Palop JJ, Puolivali J, Massaro C, Bien-Ly N, Gerstein H, et al. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci. 2005;25(42):9694-703.
44. Coffee B, Keith K, Albizua I, Malone T, Mowrey J, Sherman SL, et al. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet. 2009;85(4):503-14.
45. Tranfaglia MR. The psychiatric presentation of fragile x: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome. Dev Neurosci. 2011;33(5):337-48.
46. Bassell GJ, Warren ST. Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron. 2008;60(2):201-14.
47. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004;27(7):370-7.
48. Li Z, Zhang Y, Ku L, Wilkinson KD, Warren ST, Feng Y. The fragile X mental retardation protein inhibits translation via interacting with mRNA. Nucleic Acids Res. 2001;29(11):2276-83.
49. Antar LN, Bassell GJ. Sunrise at the synapse: the FMRP mRNP shaping the synaptic interface. Neuron. 2003;37(4):555-8.
50. Darnell JC, Van Driesche SJ, Zhang C, Hung KYS, Mele A, Fraser CE, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell. 2011;146(2):247-61.
51. Hou L, Antion MD, Hu D, Spencer CM, Paylor R, Klann E. Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. Neuron. 2006;51(4):441-54.
52. Zalfa F, Giorgi M, Primerano B, Moro A, Di Penta A, Reis S, et al. The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell. 2003;112(3):317-27.
53. Lu R, Wang H, Liang Z, Ku L, O'Donnell WT, Li W, et al. The fragile X protein controls microtubule-associated protein 1B translation and microtubule stability in brain neuron development. Proc Natl Acad Sci USA. 2004;101(42):15201-6.
54. Huber KM, Gallagher SM, Warren ST, Bear MF. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA. 2002;99(11):7746-50.
55. Goebel-Goody S, Wilson-Wallis ED, Royston S, Tagliatela SM, Naegele JR, Lombroso PJ. Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model. Genes Brain Behav. 2012;11(5):586-600.
56. Westmark CJ, Malter JS. FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biology. 2007;5(3):e52.
57. Westmark CJ, Westmark PR, O'Riordan KJ, Ray BC, Hervey CM, Salamat MS, et al. Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice. PloS One. 2011;6(10):e26549.
58. Javitt DC. Glutamatergic theories of schizophrenia. Isr J Psychiatry Relat Sci. 2010;47(1):4-16.
59. Rossler W, Salize HJ, van Os J, Riecher-Rossler A. Size of burden of schizophrenia and psychotic disorders B. Eur Neuropsychopharmacol. 2005;15(4):399-409.
60. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry. 2001;158(9):1367-77.
61. Gao X, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: Effects of Schizophrenia. Am J Psychiatry. 2000;157(7):1141-9.
62. Ibrahim HM, Hogg AJ Jr., Healy DJ, Haroutunian V, Davis KL, Meador-Woodruff JH. Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am J Psychiatry. 2000;157(11):1811-23.
63. Stephan KE, Friston KJ, Frith CD. Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. Schizophr Bull. 2009;35(3):509-27.
64. Krystal JH, D'Souza DC, Petrakis IL, Belger A, Berman RM, Charney DS, et al. NMDA Agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry. 1999;7(3):125-43.
65. Bubenikova-Valesova V, Horacek J, Vrajova M, Hoschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev. 2008;32(5):1014-23.
66. Carty NC, Xu J, Kurup P, Brouillette J, Goebel-Goody SM, Austin DR, et al. The tyrosine phosphatase STEP: implications in schizophrenia and the molecular mechanism underlying antipsychotic medications. Transl Psychiatry. 2012;2:e137.
67. Bousman CA, Chana G, Glatt SJ, Chandler SD, May T, Lohr J, et al. Positive symptoms of psychosis correlate with expression of ubiquitin proteasome genes in peripheral blood. Am J Med Genet B Neuropsychiatr Genet. 2010;153B(7):1336-41.
68. Bousman CA, Chana G, Glatt SJ, Chandler SD, Lucero GR, Tatro E, et al. Preliminary evidence of ubiquitin proteasome system dysregulation in schizophrenia and bipolar disorder: convergent pathway analysis findings from two independent samples. Am J Med Genet B Neuropsychiatr Genet. 2010;153B(2):494-502.
69. Barr AJ. Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development. Future Med Chem. 2010;2(10):1563-76.
70. Eswaran J, von Kries JP, Marsden B, Longman E, Debreczeni JE, Ugochukwu E, et al. Crystal structures and inhibitor identification for PTPN5, PTPRR and PTPN7: a family of human MAPK-specific protein tyrosine phosphatases. Biochem J. 2006;395(3):483-91.
71. Barr AJ, Knapp S. MAPK-specific tyrosine phosphatases: new targets for drug discovery? Trends Pharmacol Sci. 2006;27(10):525-30.
72. Goebel-Goody SM, Baum M, Paspalas CD, Fernandez SM, Carty NC, Kurup P, et al. Therapeutic implications for striatal-enriched protein tyrosine phosphatase (STEP) in neuropsychiatric disorders. Pharmacol Rev. 2012;64(1):65-87.